Feasibility and Safety of Interleukin-1 Blockade to Treat Cardiac Sarcoidosis

IL-1 阻断治疗心脏结节病的可行性和安全性

• 批准号: 10078287
• 负责人: Antonio Abbate
• 金额: $ 26.5万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-01-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10078287
• 关键词: Address; Adrenal Cortex Hormones; Affect; African American; American Heart Association; Anti-Inflammatory Agents; Architecture; Arrhythmia; Attenuated; Biological Markers; C-reactive protein; Cardiac; Cardiac Electrophysiologic Techniques; Cardiac Sarcoidosis; Cardiomyopathies; Cardiovascular Diseases; Cardiovascular system; Cessation of life; Clinical; Clinical Trials; Collaborations; Complex; Controlled Clinical Trials; Country; Data; Diagnosis; Diagnostic; Disease; Double-Blind Method; Event; Functional disorder; Future; Granuloma; Granulomatous; Health; Heart; Heart Diseases; Heart failure; Human; Inflammasome; Inflammation; Inflammatory; Inflammatory Response; Interleukin-1; Interleukin-1 Receptors; Interleukin-6; International; Kineret; Lead; Leadership; Life; Literature; Liver; Lung; Measures; Michigan; Minority; Molecular; Monitor; Myocardial; Myocardial Ischemia; Myocarditis; Natural History; Organ; Outcome; Patients; Pharmaceutical Preparations; Phase; Pilot Projects; Placebos; Plasma; Population Heterogeneity; Predictive Value; Protein Biosynthesis; Recombinant Interleukin-1; Registries; Research; Research Personnel; Research Proposals; Resources; Role; Sarcoidosis; Severity of illness; Societies; Steroids; Subgroup; Surrogate Endpoint; Sweden; Testing; Tissues; Translating; Translational Research; Universities; Virginia; Woman; Work; adverse outcome; anakinra; base; body system; cardioprotection; chronic inflammatory disease; clinical application; clinical care; cytokine; design; effective therapy; feasibility testing; heart rhythm; improved; improved outcome; innovation; interest; member; novel; novel therapeutic intervention; phase 3 study; pre-clinical; pre-clinical research; randomized placebo-controlled clinical trial; recruit; response; safety and feasibility; side effect; standard care; systemic inflammatory response; targeted treatment; therapy development; translational scientist

SUMMARY Sarcoidosis is an inflammatory disease that can affect any organ system. Rarely, sarcoidosis can affect the heart, leading to life-threatening heart rhythm problems, heart failure, and death. There are no drugs specifically approved for the treatment of sarcoidosis. Remarkably, despite >50 years of use as the most common therapy for sarcoidosis, there is no proof that corticosteroid treatment works for cardiac sarcoidosis. Preliminary data indicate a role for interleukin-1, the prototypical cytokine, in granuloma formation in sarcoidosis and we have shown evidence of IL-1 inflammasome formation in cardiac tissue of patients with cardiac sarcoidosis. Clinical trials have shown that IL-1 blockers can improve outcomes in ischemic heart disease and heart failure. Our research seeks to evaluate whether IL-1 blockade with the IL-1 receptor antagonist, anakinra, can safely modulate systemic inflammation in patients with active cardiac sarcoidosis. IL- 1 blockade is a novel therapeutic strategy that has not been tested in cardiac sarcoidosis. We have designed a double-blind randomized placebo-controlled clinical trial of anakinra, an IL-1 receptor blocker, given for 4 weeks in 28 patients with cardiac sarcoidosis. We will determine feasibility of recruitment and tolerability of treatment with anakinra in cardiac sarcoidosis patients and determine the effects of anakinra on systemic inflammation as measured by C reactive protein and IL-6, inflammatory biomarkers shown to be surrogates for cardiovascular outcomes. The study will build on the collaboration of two CTSA hubs that are international leaders in cardiac sarcoidosis clinical care – Virginia Commonwealth University and the University of Michigan, under the translational research leadership of Dr. Antonio Abbate, an expert in cardiac inflammation. This proposal addresses urgent unmet needs that are common to both the National Center for Advancing Translational Sciences (NCATS) and the American Heart Association (AHA) - defined as the need of translating biomedical discoveries into clinical applications to improve human health and specifically of developing therapies to attenuate disease impact of cardiac sarcoidosis – a condition for which no targeted therapy exists. The results of this pilot study will serve as proof-of-concept data to conceive future phase III studies involving CTSA hubs across the country. A novel targeted treatment could bring about a much-needed paradigm shift in the treatment of cardiac sarcoidosis.

概括 结节病是一种炎症性疾病，可能影响任何器官系统。结节病很少会影响 心脏，导致威胁生命的心律问题，心力衰竭和死亡。没有专门的药物 批准治疗结节病。值得注意的是，任务> 50年作为最常见的疗法 对于结节病，没有证据表明皮质类固醇治疗可用于心脏结节病。 初步数据表明白介素-1（原型细胞因子）在肉芽肿形成中的作用 结节病，我们已经显示出患有心脏组织IL-1炎性体形成的证据 心脏结节病。临床试验表明，IL-1阻滞剂可以改善缺血性心脏的预后 疾病和心力衰竭。我们的研究旨在评估IL-1是否与IL-1接收器进行封锁 拮抗剂Anakinra可以安全地调节活性心脏结节病患者的全身性炎症。 il- 1桶是一种新型的热策略，尚未在心脏结节病中进行测试。我们设计了一个 IL-1受体阻滞剂Anakinra的双盲随机安慰剂对照临床试验，持续4周 在28例心脏结节病患者中。我们将确定招募和治疗耐受性的可行性 与阿纳基拉（Anakinra 通过C反应性蛋白和IL-6测量，炎症生物标志物被证明是心血管的替代物 结果。这项研究将基于两个CTSA枢纽的合作，这些CTSA枢纽是心脏领域的国际领导者 结节病临床护理 - 弗吉尼亚联邦大学和密歇根大学， 心脏感染专家Antonio Abbate博士的转化研究领导。 该提案解决了国家前进中心共有的紧急未满足需求 翻译科学（NCAT）和美国心脏协会（AHA） - 被定义为翻译 生物医学发现到临床应用中，以改善人类健康，特别是开发疗法 减轻心脏结节病的疾病影响 - 这种疾病不存在靶向疗法。结果 这项试验研究将作为概念证明数据，以构想未来的III期研究涉及CTSA集线器 在全国范围内。一种新颖的目标治疗可能会导致治疗中急需的范式转移 心脏结节病。

项目成果

Methylphenidate Effects on Cortical Thickness in Children and Adults with Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.

哌醋甲酯对患有注意力缺陷/多动症的儿童和成人皮质厚度的影响：一项随机临床试验。

• DOI: 10.3174/ajnr.a6560
• 发表时间: 2020
• 期刊: AJNR. American journal of neuroradiology
• 作者: Walhovd,KB;Amlien,I;Schrantee,A;Rohani,DA;Groote,I;Bjørnerud,A;Fjell,AM;Reneman,L
• 通讯作者: Reneman,L